Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of KBP-5074 for uncontrolled hypertension in moderate to severe chronic kidney disease
NL-OMON51892Phase 3Withdrawn
- Sponsor
- KBP Biosciences
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in resistant hypertension (RH) and chronic kidney disease (CKD) comparing KBP-5074 with Placebo (2 arms). Primary endpoints: Change in seated trough cuff systolic blood pressure from baseline to Week 12 and Change in seated trough cuff systolic blood pressure from Week 48 to Week 52. Planned start Apr 2022; status: withdrawn.
02
Drugs
ocederenone
03
Conditions
resistant hypertension (RH)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON51892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51892.